Danaher Co. (DHR) Position Decreased by Oakbrook Investments LLC

Oakbrook Investments LLC cut its holdings in shares of Danaher Co. (NYSE:DHR) by 4.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,250 shares of the conglomerate’s stock after selling 1,450 shares during the quarter. Oakbrook Investments LLC’s holdings in Danaher were worth $2,901,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. GQG Partners LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $101,000. Zions Bancorporation increased its holdings in shares of Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after acquiring an additional 667 shares during the last quarter. Patten Group Inc. increased its holdings in shares of Danaher by 262.3% during the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 3,497 shares during the last quarter. Monetary Management Group Inc. increased its holdings in shares of Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after acquiring an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC increased its holdings in shares of Danaher by 185.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after acquiring an additional 1,100 shares during the last quarter. 76.11% of the stock is currently owned by institutional investors and hedge funds.

DHR has been the topic of a number of recent analyst reports. Credit Suisse Group reissued a “hold” rating and set a $99.00 target price on shares of Danaher in a report on Tuesday, December 19th. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and issued a $99.00 price objective on shares of Danaher in a report on Friday, December 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $86.00) on shares of Danaher in a report on Friday, October 6th. Finally, Cowen reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Danaher in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $94.91.

Shares of Danaher Co. (NYSE:DHR) traded up $0.12 during midday trading on Thursday, reaching $99.59. The company’s stock had a trading volume of 2,542,800 shares, compared to its average volume of 2,493,373. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Co. has a 52-week low of $78.97 and a 52-week high of $100.27. The firm has a market cap of $69,280.00, a price-to-earnings ratio of 29.64, a price-to-earnings-growth ratio of 2.16 and a beta of 1.03.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The firm had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same period in the prior year, the firm posted $0.87 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. research analysts expect that Danaher Co. will post 3.99 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio is 16.67%.

In other news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the sale, the chief executive officer now owns 271,737 shares of the company’s stock, valued at $25,173,715.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 273,810 shares of company stock valued at $25,218,813. Corporate insiders own 12.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Danaher Co. (DHR) Position Decreased by Oakbrook Investments LLC” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://transcriptdaily.com/2018/01/18/danaher-co-dhr-position-decreased-by-oakbrook-investments-llc.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply